IntraGel secures $7M from UroGen for cancer therapy development

Nazareth, Israel - IntraGel Therapeutics has secured an equity investment from UroGen Pharma Ltd. (NASDAQ:URGN) for a maximum of $7 million to advance Phase 2 trials of TumoCure, a potential cancer treatment for advanced head and neck cancer. This agreement also grants UroGen an exclusive option to obtain global rights to develop and market TumoCure after IntraGel's Phase 2 study concludes, as reported in a press release.

In addition to the investment, UroGen gains access to IntraGel's SRGel platform, a biodegradable, sustained-release drug delivery technology, with the option to license up to three more oncology products. TumoCure is a cisplatin formulation using IntraGel's SRGel technology, intended to provide prolonged localized drug exposure while minimizing systemic exposure.

Phase 1b clinical data from the 2026 American Society of Clinical Oncology Annual Meeting indicated that TumoCure was generally safe, well-tolerated, and showed early signs of anti-tumor activity in patients who had not responded to multiple rounds of cisplatin therapy. The SRGel platform is a water-free and solvent-free polymer technology compatible with various drug types.

IntraGel is targeting patients with locally advanced, inoperable head and neck cancers who are not suitable for standard cisplatin-based chemoradiation. The company is also exploring additional therapies using the SRGel platform, such as IG-003 with GLP-1 analogues for weight management and monoclonal antibody and peptide programs through current collaborations.